Search Results
Aug 07, 2025, 06:25 ET Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
demonstrate that orforglipron (6 mg, 12 mg, 36 mg) is superior to placebo in body weight reduction from baseline after 72 weeks in people with a BMI ≥30.0 kg/m² or a BMI ≥27.0 kg/m² with at least one weight-related comorbidity and a history of at least one self-reported unsuccessful dietary effort to lose body
More news about: Eli Lilly and Company
Aug 06, 2025, 08:31 ET MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
therapeutic profile across primary, secondary and exploratory endpoints—including safety, tolerability, body weight, waist circumference, and body mass index (BMI), among others—and to further unlock its full therapeutic potential. Previously reported data from the 32 mg dose demonstrated strong weight loss effects
More news about: MetaVia Inc.
Aug 05, 2025, 08:00 ET Currax Announces National Expansion of "Cravings Don't Own Me" CTV Commercial, Along with Launch of New "Real Patients, Real Results" DTC Campaign
reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol,
More news about: Currax Pharmaceuticals LLC
Aug 05, 2025, 06:50 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight
placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 but < 30 kg/m2) with at least one weight-related comorbidity. Two oral formulations of one-daily
More news about: Ascletis Pharma Inc.
Aug 04, 2025, 13:00 ET BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends
More news about: BMI OrganBank
Jul 31, 2025, 08:00 ET Radella Pharmaceuticals Announces New Obesity Trial Data Showing Statistically Significant Weight Loss and Broader Cardiometabolic Benefits
double‑blind, placebo‑controlled multiple ascending dose (MAD) Phase 1b trial enrolled healthy volunteers [n=36] with an average body‑mass index (BMI) of 28.8 +2.5 in the MD-18 arm. Participants received either placebo or escalating weekly doses of MD‑18 for four weeks without titration. The
More news about: Radella Pharmaceuticals
Jul 30, 2025, 11:04 ET Gnosis Launches EdenDx, the First Non-Invasive Liquid-Based Cytology U.S. Test for Early Endometrial Cancer Detection
index (BMI), a history of endometrial hyperplasia, or increased risk due to Tamoxifen therapy or Lynch syndrome. Today, tens of millions of women fall into these high-risk categories. In the United States alone, over 34 million women live with elevated BMI, approximately
More news about: Gnosis
Jul 29, 2025, 11:57 ET GRAMMY AWARD-WINNING ARTIST, PRODUCER, AND SONGWRITER T-PAIN TO RECEIVE THE BMI PRESIDENT'S AWARD AT THE 2025 BMI R&B/HIP-HOP AWARDS
BMI announced today that GRAMMY® Award-winning artist, producer, songwriter, entrepreneur and global cultural icon T-Pain will receive the BMI President's Award at the 2025 BMI R&B/Hip-Hop Awards
More news about: Broadcast Music, Inc.
Jul 27, 2025, 20:15 ET Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30
placebo-controlled and multi-center study to evaluate the safety, tolerability and efficacy in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 but < 30 kg/m2) with at least one weight-related comorbidity. The study consists of three cohorts
More news about: Ascletis Pharma Inc.
Jul 24, 2025, 08:36 ET CITY OF LONDON INVESTMENT GROUP PLC ("City of London" or "the Group" or "the Company" or "CLIG") PRE-CLOSE TRADING UPDATE FOR THE YEAR ENDED 30 JUNE 2025
presented as net of fees performance figures. The CLIM Global Emerging Markets strategy is shown against the S&P Emerging Frontier Super Composite BMI Net TR Index, the CLIM Global Developed CEF International Equity Strategy is shown against the MSCI ACWI ex-US Net TR Index, the CLIM Opportunistic Value
More news about: City of London Investment Group PLC
Jul 23, 2025, 16:05 ET Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
injection once weekly for 78 weeks. The VANQUISH-1 study will target enrollment of approximately 4,500 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study will target enrollment of
More news about: Viking Therapeutics, Inc.
Jul 22, 2025, 10:45 ET myBasePay Appoints Angela Alberty as Chief Executive Officer, Ushering in New Era of Workforce Innovation and Inclusive Leadership
of workforce leadership and the board unanimously agreed to her appointment as CEO," said Andrew Sierra, President of BMI Financial Group, Inc. and Board Member of myBasePay. "Her unique combination of ground- level industry experience, strategic vision, and innovation ensures
More news about: myBasePay
Jul 15, 2025, 10:10 ET Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol,
More news about: Currax Pharmaceuticals LLC
Jul 14, 2025, 16:35 ET Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
taking CRENESSITY experienced greater reductions in body mass index (BMI) at Week 24 versus placebo, with further reductions from baseline observed through Month 12.Pediatric patients taking CRENESSITY saw reductions in BMI standard deviation scores (SDS) at Week 28, while those taking placebo
More news about: Neurocrine Biosciences, Inc.
Jul 09, 2025, 14:45 ET Two-faced gene variant appears good for men, bad for women
the people sampled in the two biobanks had the rs6190 variant. However, the men who had it tended to show lower BMI, more lean mass and higher hand grip strength. Similar trends were found in women but with smaller magnitude. However, the team determined that
More news about: Cincinnati Children's Hospital Medical Center
Jul 09, 2025, 12:00 ET BMI Imaging Exhibits at 2025 FACRAO Summit in Orlando
goals." BMI specializes in converting paper files and microfilm into easily accessible digital formats, helping institutions enhance long-term preservation and simplify daily access to critical data. With secure hosting options—ranging from private cloud to CJIS-compliant platforms—BMI ensures that
More news about: BMI Imaging Systems, Inc.
Jul 09, 2025, 08:31 ET MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose
single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects. The study enrolled healthy adults with a minimum body mass index (BMI) between 30 – 45 kg/m2. Nine subjects in each cohort are being randomized in a 6:3 ratio, with each subject receiving either 4 weekly administrations
More news about: MetaVia Inc.
Jul 02, 2025, 19:00 ET Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 but < 30 kg/m2) with at least one weight-related comorbidity. Two oral formulations of ASC30,
More news about: Ascletis Pharma Inc.
Jul 01, 2025, 08:30 ET PhaseV Announces New ClinOps AI Platform: Transforming Clinical Trial Operations with Precision-Guided Site Selection
the factors that drive site variability and patient heterogeneity. The ClinOps platform takes into account patient-level covariates, including age, BMI, ethnicity, comorbidities, genomics, and prior treatments, aligning with the mechanism of action (MoA) of the therapeutic asset and eligibility criteria.
More news about: PhaseV
Jun 30, 2025, 11:50 ET Heavy Construction Equipment Market Size worth $338.06 billion by 2031, Globally, at a CAGR of 6.16%, Rising demand for material handling equipment in warehouse sector | Business Market Insights
June 30, 2025 /PRNewswire/ -- According to a new comprehensive report from Business Market Insights [BMI], "Heavy Construction Equipment Market Size and Forecast (2021–2031)" forecasts how the market is set to surge 51% by 2031 as Warehouse and Logistics
More news about: Business Market Insights
Jun 30, 2025, 11:32 ET 3D and 4D Technology Market Size to Hit USD 1100.92 Billion by 2031 With a CAGR of 18.5%, Growing Technological Advancement and Consumer Demand to Drive Market | Business Market Insights
June 30, 2025 /PRNewswire/ -- According to a new comprehensive report from Business Market Insights [BMI] "3D & 4D Technology Market Size and Forecast (2021–2031)" forecasts how the market is set to surge 222% by 2031 as Technology
More news about: Business Market Insights
Jun 30, 2025, 08:30 ET Afaxys and Exeltis Renew Partnership to Expand Access to Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System
index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Healthcare providers (HCPs) are encouraged to consider Twirla's reduced efficacy in women with a BMI ≥ 25 to <30 kg/m2 before prescribing. Twirla is contraindicated in women with a BMI ≥ 30 kg/m2.
More news about: Afaxys, Inc.
Jun 28, 2025, 00:11 ET New Radicals Gregg Alexander Wins BMI Pop Award for "Murder on the Dance Floor" Two Decades After His mid-2000's Song of the Year "Game of Love" Performance Is Unearthed in a Storage Unit After a Family Tragedy
Watch Game of Love performed at BMI Awards from 2005. "MURDER ON THE DANCEFLOOR" WAS ONE OF RADIO, TIKTOK AND STREAMING'S MOST PLAYED SONGS OF 2024 SPURRED
More news about: Big Hassle Media
Jun 27, 2025, 05:49 ET Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management
diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of: BMI ≥ 28 kg/m² (obesity); orBMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension,
More news about: Innovent Biologics
Jun 25, 2025, 11:15 ET With 20.4% of CAGR, Web Content Management Market Size to Gain $33.32 Billion by 2031
North America latest BMI insight Market Reports - https://www.businessmarketinsights.com/reportstore For Europe latest BMI insight Market Reports -
More news about: Business Market Insights